Noscapine Enhances Doxorubicin Activity in Triple Negative Breast Cancer
Author Information
Author(s): Chougule Mahavir B., Patel Apurva R., Jackson Tanise, Singh Mandip
Primary Institution: College of Pharmacy, Florida A&M University
Hypothesis
Noscapine in combination with Doxorubicin will produce additive or synergistic cytotoxic effects in human TNBC in vitro and in vivo possibly by inactivation of NF-KB and also via antiangiogenic and apoptotic activity.
Conclusion
Noscapine potentiated the anticancer activity of Doxorubicin in a synergistic manner against TNBC tumors via inactivation of NF-KB and anti-angiogenic pathways while stimulating apoptosis.
Supporting Evidence
- Noscapine inhibited growth of MDA-MB-231 and MDA-MB-468 cells with IC50 values of 36.16±3.76 and 42.7±4.3 µM respectively.
- The combination treatment showed significant increase in apoptotic cells.
- Noscapine reduced tumor volume by 39.4±5.8% compared to controls.
Takeaway
This study shows that a medicine called Noscapine can help another medicine, Doxorubicin, work better against a type of breast cancer that is hard to treat.
Methodology
The study involved treating TNBC cells with Noscapine and Doxorubicin, assessing apoptosis through TUNEL staining, and evaluating tumor growth in mice xenografted with TNBC cells.
Limitations
The study primarily focused on specific cell lines and may not fully represent all TNBC cases.
Participant Demographics
Female athymic Nu/nu mice were used for in vivo experiments.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website